Event Abstract Back to Event Hepatoprotection by probiotics in vivo: a systematic review and meta-analysis Faezah Sabirin1, 2, 3, Siong Meng Lim1, 2, Chin Fen Neoh1, 2 and Kalavathy Ramasamy1, 2* 1 Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Malaysia 2 Collaborative Drug Discovery Research (CDDR) Group, Universiti Teknologi MARA (UiTM), Pharmaceutical and Life Sciences Community of Research, Malaysia 3 Faculty of Dentistry, Universiti Teknologi MARA, Malaysia Background The severity of nonalcoholic fatty liver disease (NAFLD) has been found to be associated with gut dysbiosis. Probiotics, which are beneficial in maintaining a healthy gut, may be useful in delaying development of NAFLD. This study was undertaken to systematically review and analyse the impact of evidence pertaining to probiotic supplementation in NAFLD in vivo. Methods Literature search was conducted between October 2017 - May 2018 using Cochrane, PubMed/ MEDLINE, Embase, Springer and Web of Science. Article identification and data extraction were performed by four reviewers based on inclusion and exclusion criteria. Risk of bias was assessed using SYRCLE tool. Meta-analysis was performed using RevMan 5.3. The primary outcomes included severity of liver histopathology [i.e. total NAFLD activity score (NAS)] and serum alanine aminotransferase (ALT). The secondary outcomes included hepatic lipid and triglyceride, as well as serum triglyceride, HDL and LDL cholesterol. Mean differences (MD) or standard MD (SMD) between groups were analysed using Random-Effect Model. Statistical heterogeneity was assessed using I2 test. Results Twenty-eight studies were included in the systematic review whilst only 9 were selected for subsequent meta-analysis. The shortlisted literature was predominantly presented with low or unclear risk of bias. When compared to control, the total NAS was significantly lower in probiotic group (MD=-1.81; 95% CI=-2.37, -1.24, p<0.00001). The heterogeneity was moderate but insignificant (I2=55%, p=0.05). Significant reduction in ALT was noted in probiotic group (MD=-0.99; 95% CI=-1.55, -0.43, p=0.0005). The heterogeneity was, however, substantial (I2=70%, p<0.0001) when compared to control. The significant reduction in total NAS was accompanied by significantly lower hepatic lipid (p<0.00001) and triglyceride (p<0.0001). Nevertheless, no significant changes were noted in other serum parameters. Conclusion Probiotic supplementation was associated with significant reduction in total NAS and ALT. The present findings strongly implied the hepatoprotective potential of proboitics. Keywords: Dysbiosis, Hepatic lipid, ALT, NAFLD (non alcoholic fatty liver disease), Probiotics, total NAFLD activity score, hepatic triglyceride Conference: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019. Presentation Type: Oral Presentation Topic: Metabolic diseases Citation: Sabirin F, Lim S, Neoh C and Ramasamy K (2019). Hepatoprotection by probiotics in vivo: a systematic review and meta-analysis. Front. Pharmacol. Conference Abstract: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”. doi: 10.3389/conf.fphar.2018.63.00140 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 22 Oct 2018; Published Online: 17 Jan 2019. * Correspondence: Dr. Kalavathy Ramasamy, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM), Bandar Puncak Alam, Selangor Darul Ehsan, Malaysia, kalav922@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Faezah Sabirin Siong Meng Lim Chin Fen Neoh Kalavathy Ramasamy Google Faezah Sabirin Siong Meng Lim Chin Fen Neoh Kalavathy Ramasamy Google Scholar Faezah Sabirin Siong Meng Lim Chin Fen Neoh Kalavathy Ramasamy PubMed Faezah Sabirin Siong Meng Lim Chin Fen Neoh Kalavathy Ramasamy Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
Read full abstract